focus -WSS

focus

author：focus 2025-08-28 08:40:39 - browse：54726

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Cancer diagnosis changes perspective doctor, former hospital CEO

WSS

Hubble vs. James Webb telescope images: See the difference

Hubble vs. James Webb telescope images: See the difference

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Lupron, used to halt puberty in children, may cause lasting health problems

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

In age of alternative facts, a scholarly course on calling out crap

'Screen and refer' systems are hurting patients

Trump demands the U.S. pay no more for drugs than other countries … again

FDA reorg will put new emphasis on investigations, sources say

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Guidelines to prevent youth baseball injuries need more muscle

Security flaws in third

Medicare proposal to cover medical devices draws a mixed reaction

White House drug czar issues call for 'recovery

explore

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

A letter from the executive editor: The 2023 STATUS List

Ventyx halts psoriasis drug development after lackluster trial results

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

The wait for US passports is creating travel purgatory and snarling summer plans

Undocumented workers face uncertainty as immigration law takes effect in Florida

entertainment

knowledge

knowledge

entertainment